417 related articles for article (PubMed ID: 28351757)
1. Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease.
Faustino C; Rijo P; Reis CP
Pharmacol Res; 2017 Jun; 120():68-87. PubMed ID: 28351757
[TBL] [Abstract][Full Text] [Related]
2. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor.
Ferreira D; Westman E; Eyjolfsdottir H; Almqvist P; Lind G; Linderoth B; Seiger A; Blennow K; Karami A; Darreh-Shori T; Wiberg M; Simmons A; Wahlund LO; Wahlberg L; Eriksdotter M
J Alzheimers Dis; 2015; 43(3):1059-72. PubMed ID: 25147108
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine for the treatment of Alzheimer's disease.
Gregori M; Masserini M; Mancini S
Nanomedicine (Lond); 2015; 10(7):1203-18. PubMed ID: 25929574
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device.
Eyjolfsdottir H; Eriksdotter M; Linderoth B; Lind G; Juliusson B; Kusk P; Almkvist O; Andreasen N; Blennow K; Ferreira D; Westman E; Nennesmo I; Karami A; Darreh-Shori T; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger Å; Wahlberg L; Almqvist P
Alzheimers Res Ther; 2016 Jul; 8(1):30. PubMed ID: 27389402
[TBL] [Abstract][Full Text] [Related]
5. Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease.
Lad SP; Neet KE; Mufson EJ
Curr Drug Targets CNS Neurol Disord; 2003 Oct; 2(5):315-34. PubMed ID: 14529363
[TBL] [Abstract][Full Text] [Related]
6. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
[TBL] [Abstract][Full Text] [Related]
7. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
[TBL] [Abstract][Full Text] [Related]
8. Painless Nerve Growth Factor: A TrkA biased agonist mediating a broad neuroprotection via its actions on microglia cells.
Cattaneo A; Capsoni S
Pharmacol Res; 2019 Jan; 139():17-25. PubMed ID: 30391352
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
Fonseca-Santos B; Gremião MP; Chorilli M
Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
[TBL] [Abstract][Full Text] [Related]
10. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives.
Harilal S; Jose J; Parambi DGT; Kumar R; Mathew GE; Uddin MS; Kim H; Mathew B
J Pharm Pharmacol; 2019 Sep; 71(9):1370-1383. PubMed ID: 31304982
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective Effect of Nerve Growth Factor Loaded in Porous Silicon Nanostructures in an Alzheimer's Disease Model and Potential Delivery to the Brain.
Zilony-Hanin N; Rosenberg M; Richman M; Yehuda R; Schori H; Motiei M; Rahimipour S; Groisman A; Segal E; Shefi O
Small; 2019 Nov; 15(45):e1904203. PubMed ID: 31482695
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound delivery of a TrkA agonist confers neuroprotection to Alzheimer-associated pathologies.
Xhima K; Markham-Coultes K; Hahn Kofoed R; Saragovi HU; Hynynen K; Aubert I
Brain; 2022 Aug; 145(8):2806-2822. PubMed ID: 34919633
[TBL] [Abstract][Full Text] [Related]
13. Wheat germ agglutinin-conjugated liposomes incorporated with cardiolipin to improve neuronal survival in Alzheimer's disease treatment.
Kuo YC; Lin CY; Li JS; Lou YI
Int J Nanomedicine; 2017; 12():1757-1774. PubMed ID: 28280340
[TBL] [Abstract][Full Text] [Related]
14. Promising Therapies for Alzheimer's Disease.
Confaloni A; Tosto G; Tata AM
Curr Pharm Des; 2016; 22(14):2050-6. PubMed ID: 26876218
[TBL] [Abstract][Full Text] [Related]
15. Nerve growth factor in treatment and pathogenesis of Alzheimer's disease.
Williams BJ; Eriksdotter-Jonhagen M; Granholm AC
Prog Neurobiol; 2006 Oct; 80(3):114-28. PubMed ID: 17084014
[TBL] [Abstract][Full Text] [Related]
16. Nerve Growth Factor Gene Therapy: Activation of Neuronal Responses in Alzheimer Disease.
Tuszynski MH; Yang JH; Barba D; U HS; Bakay RA; Pay MM; Masliah E; Conner JM; Kobalka P; Roy S; Nagahara AH
JAMA Neurol; 2015 Oct; 72(10):1139-47. PubMed ID: 26302439
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's Disease Targeted Nano-Based Drug Delivery Systems.
Altinoglu G; Adali T
Curr Drug Targets; 2020; 21(7):628-646. PubMed ID: 31744447
[TBL] [Abstract][Full Text] [Related]
18. A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer's Disease.
Mitra S; Gera R; Linderoth B; Lind G; Wahlberg L; Almqvist P; Behbahani H; Eriksdotter M
Adv Exp Med Biol; 2021; 1331():167-191. PubMed ID: 34453298
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine Strategies for Sustained, Controlled and Targeted Treatment of Alzheimer's Disease.
Ma TJ; Gao J; Liu Y; Zhuang JH; Yin C; Li P; Mao L; Xu J; Xu YX; Li YP; Zhao ZX; Yin Y
Mini Rev Med Chem; 2018; 18(12):1035-1046. PubMed ID: 29243575
[TBL] [Abstract][Full Text] [Related]
20. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice.
De Rosa R; Garcia AA; Braschi C; Capsoni S; Maffei L; Berardi N; Cattaneo A
Proc Natl Acad Sci U S A; 2005 Mar; 102(10):3811-6. PubMed ID: 15728733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
